---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000051"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-09-07T23:59:59+00:00"
generated_at: "2026-06-10T22:33:56.854624+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Roche delays US launch of Tecentriq SC with Halozyme's ENHANZE to 2024

## Summary
- Roche informed Halozyme on Sept 6, 2023 of US launch delay for Tecentriq SC due to required CMC updates.
- CMC process updates expected to finish in 2023, enabling potential US launch in 2024.
- Ex-US filings for Tecentriq SC remain unaffected by the delay.
- Delay could impact Halozyme's royalty revenue from US sales until 2024.

## SEC filing metadata
- accession: 0001159036-23-000051
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-09-07T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000051/0001159036-23-000051-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000051/halo-20230906.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000051
- JSON: https://secwatch.observer/filing/0001159036-23-000051.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000051.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.